@article{3de12499009d40adb4ab128276fd7f7c,
title = "Novel personalized cancer vaccine platform based on Bacillus Calmette-Guerin",
keywords = "adaptive immunity, immunity, cellular, immunogenicity, vaccine, immunotherapy, active, ADVANCED MELANOMA PATIENTS, MYCOBACTERIUM-BOVIS BCG, PRIME-BOOST VACCINATION, TOPICAL IMIQUIMOD, IMMUNE-RESPONSES, SURFACE-CHARGE, B16 MELANOMA, TUMOR-GROWTH, VIRUS, IMMUNOTHERAPY, 3122 Cancers, 317 Pharmacy",
author = "Erkko Yl{\"o}sm{\"a}ki and Manlio Fusciello and Beatriz Martins and Sara Feola and Firas Hamdan and Jacopo Chiaro and Leena Yl{\"o}sm{\"a}ki and Vaughan, {Matthew J.} and Tapani Viitala and Kulkarni, {Prasad S.} and Vincenzo Cerullo",
year = "2021",
doi = "10.1136/jitc-2021-002707",
language = "English",
volume = "9",
journal = "Journal for Immunotherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "7",
}